Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy

Authors

Institutions

Publication Details

Journal
Blood
Published
2024-11-05
DOI
https://doi.org/10.1182/blood-2024-201189
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy

Carmel Waldron, Richard Tsang, David Hodgson, Danielle Rodin et al.
Blood
CAR-T cell therapy research
article

Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy

Carmel Waldron, Richard Tsang, David Hodgson, Danielle Rodin, Anca Prica, Chathuri Abeyakoon, Robert Kridel, Katrina Hueniken, Nauman Malik, Michael Crump, Vishal Kukreti, Christine I. Chen, Sita Bhella, Rachel Aitken, Abi Vijenthira, John Kuruvilla, Woodrow Wells, Jing Yang
article en

Abstract

No abstract available for this paper.
BloodVol. 144(Supplement 1)
University Health Network (CA), Princess Margaret Cancer Centre (CA), St. James's Hospital (IE)
Openalex Percentile: Top 61%
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy — Carmel Waldron, Richard Tsang, et al. · Blood (2024) | TGRS Research Map | TGRS